Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning around a 2028 Keytruda patent cliff and expressed confidence in defending ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as ...

Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...